Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Viva Biotech to Pay $80 Million to Acquire SYNthesis in CRO Tieup

Viva Biotech of Shanghai will pay $80 million to acquire fellow drug CRO SYNthesis Med Chem ( Hong Kong ). SYNthesis is a preclinical small molecule drug discovery CRO that specializes in high-end pharmaceutical chemistry and synthetic chemistry services. The company has labs in Suzhou , Shanghai and Australia . SYNthesis' expertise is "downstream" from Viva's structure-based drug discovery services that it offers to biopharma customers. One month ago, Viva announced a $368 million deal to acquire an 80% stake in Zhejiang Langhua Pharma, a CDMO and API company. More details.... Stock Symbol: (HK: 1873) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.